Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of SN132D MRI contrast in suspected endometriosis
2022-000652-11Phase 2Completed
- Sponsor
- Spago Nanomedical AB
- Start
- May 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfosimer manganese in endometriosis, sponsored by Spago Nanomedical AB. Primary endpoint: MRI enhancing effect. Started May 2022; status: completed.
02
Drugs
pegfosimer manganese
03
Conditions
endometriosis
Beyond the preview
Go deeper on 2022-000652-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000652-11.